Application of a biphasic test for characterization of in vitro drug release of immediate release formulations of celecoxib and its relevance to in vivo absorption.
A biphasic in vitro test method was used to examine release profiles of a poorly soluble model drug, celecoxib (CEB), from its immediate release formulations. Three formulations of CEB were investigated in this study, including a commercial Celebrex capsule, a solution formulation (containing cosolvent and surfactant) and a supersaturatable self-emulsifying drug delivery system (S-SEDDS). The biphasic test system consisted of an aqueous buffer and a water-immiscible organic solvent (e.g., octanol) with the use of both USP II and IV apparatuses. The aqueous phase provided a nonsink dissolution medium for CEB, while the octanol phase acted as a sink for CEB partitioning. For comparison, CEB concentration-time profiles of these formulations in the aqueous medium under either a sink condition or a nonsink condition were also explored. CEB release profiles of these formulations observed in the aqueous medium from either the sink condition test, the nonsink condition test, or the biphasic test have little relevance to the pharmacokinetic observations (e.g., AUC, C(max)) in human subjects. In contrast, a rank order correlation among the three CEB formulations is obtained between the in vitro AUC values of CEB from the octanol phase up to t = 2 h and the in vivo mean AUC (or C(max)) values. As the biphasic test permits a rapid removal of drug from the aqueous phase by partitioning into the organic phase, the amount of drug in the organic phase represents the amount of drug accumulated in systemic circulation in vivo. This hypothesis provides the scientific rationale for the rank order relationship among these CEB formulations between their CEB concentrations in the organic phase and the relative AUC or C(max). In addition, the biphasic test method permits differentiation and discrimination of key attributes among the three different CEB formulations. This work demonstrates that the biphasic in vitro test method appears to be useful as a tool in evaluating performance of formulations of poorly water-soluble drugs and to provide potential for establishing an in vitro-in vivo relationship.
Shi
Yi
Y
Global Pharmaceutical and Analytical Sciences, Abbott Laboratories, IL 60064, USA. yi.shi@abbott.com
Gao
Ping
P
Gong
Yuchuan
Y
Ping
Haili
H
D002214:Capsules; D000068579:Celecoxib; D002626:Chemistry, Pharmaceutical; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D007408:Intestinal Absorption; D008954:Models, Biological; D000442:Octanols; D011720:Pyrazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D012995:Solubility; D012997:Solvents; D013449:Sulfonamides / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D014867:Water
D002214:Capsules; D052246:Cyclooxygenase 2 Inhibitors; D000442:Octanols; D011720:Pyrazoles; D012997:Solvents; D013449:Sulfonamides; D014867:Water; D000068579:Celecoxib